Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership
- COM002 is a first-in-class complement-powered immune engager based on Commit Biologics’ proprietary BiCE™ platform.
- Anne-Marie Levy Rasmussen appointed Chief Operating Officer and Dr. Benjamin Ole Wolthers as Head of Clinical Development, ahead of Phase 1 initiation. Both join Commit’s executive management team.
- Clinical trial preparations are underway, with first patient dosing expected in early 2028.
COPENHAGEN, Denmark — November 12, 2026 — Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, today announces the nomination of its first development candidate, as well as making two senior appointments, as it transitions from platform discovery to clinical development.


